Compare AURE & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AURE | IMUX |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | 66 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 75.2M |
| IPO Year | N/A | 2013 |
| Metric | AURE | IMUX |
|---|---|---|
| Price | $2.28 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 215.4K | ★ 4.7M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.51 |
| 52 Week High | $3.53 | $1.38 |
| Indicator | AURE | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 75.59 |
| Support Level | $0.29 | $0.61 |
| Resistance Level | $3.53 | N/A |
| Average True Range (ATR) | 0.40 | 0.11 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 38.43 | 89.72 |
Aurelion Inc is engaged in providing private wealth management and asset management services to high-net-worth and ultra-high-net-worth individuals by identifying and purchasing well-matched wealth management products offered by third-party providers. Its subsidiary operates a wealth management business that works with licensed product brokers in Hong Kong, currently consisting solely of insurance brokers distributing insurance products, and assists in customizing wealth management investment portfolios for clients. The Company generates revenue for its subsidiaries' wealth management business from product brokers in the form of referral fees, which are calculated based on the value of wealth management products purchased by clients from such brokers.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.